Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1990-01-25
1990-12-11
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514248, 544115, 544234, 560 53, A61K 31535, A61K 3150, C07D23736, C07D41312
Patent
active
049771523
ABSTRACT:
The invention relates to novel tricyclic derivatives which are agonists of cholinergic receptors and to drugs containing them.
These derivatives have the following formula: ##STR1## in which: X represents a group (CH.sub.2).sub.n, n representing an integer equal to 2, 3 or 4, or alternatively a vinylene group or a methylvinylene group;
REFERENCES:
patent: 4910199 (1990-03-01), Bourguignon et al.
Lang et al., Brain Research, 267, pp. 271-280 (1983).
Christie et al., Brit. J. Psychiat. 138, pp. 46-50 (1981).
Harbaugh et al., Neurosurgery, 15, pp. 514-518 (1984).
Davies, Brain Research, 171, pp. 319-327 (1979).
Worms et al., Psychopharmacology, 93: 489-493 (1987).
Young et al., Psychopharmacology, 93: 494-497 (1987).
Perio et al., Psychopharmacology, 97: 262-268 (1989).
Worms et al., Psychopharmacology, 98: 286-288 (1989).
Kopelman, Quarterly Journal of Experimental Psychology, 38A, pp. 535-573 (1986).
Birdsall et al., Atlas of Science: Pharmacology, pp. 98-100 (1987).
Bartus et al., Science, vol. 217, pp. 408-417 (1982).
Davies et al., Nature, vol. 288, pp. 279-280 (1980).
Bartus, "Evidence for a Direct Cholinergic Involvement in the Scopolamine Induced Amnesia in Monkey", Pharmacol. Biochem. Behav. 9:833-836, 1978.
Bruno et al., Muscarinic Agonist Therapy of Alzheimer's Disease, A Clinical Trial of RS 86. Arc. Neurol. 43: 659-661, 1986.
Caine, Cholinomimetic Treatment Fails to Improve Memory Disorders, N. Engl. Med. 303: 585-586, 1980.
Chermet et al., Profils Psyshopharmacologiques de la Pilocarpine, de l'oxotremorine et de l'eserine, J. Pharmacol (Paris) 7: 227-240, 1976.
Christie et al., Physostigmine and Arecoline: Ettects of Intravenous Infusions in Alzheimer Persenile Dementia, Br. J. Psychiatry 138: 46-50, 1981.
Cummings et al., A Clinical Approach, Stoneham, Mass., Butterworths, 1983, pp. 36-56.
Enz et al., Pharmacological and Behavioural Effects of Pilocarpine, International Symposium on Muscarinic Cholinergic Mechanisms, Preund Publishing Houst Ltd. London, U.K. 1987, pp. 120-124.
Fisher et al., (Cis)--2--Methyl--Spiro--(1,3--Oxathiolane--5,3) Quinuclidine (AF 102B) A Novem Putative M1 Agonist as a Candidate Drug for the Treatment of Senile Dementia of Alzheimer's Type, International Symposium on Muscarinic Cholinergic Mechanism, Freund Publishing Houst Ltd. London, U.K. 1987, pp. 132-137.
Harbaugh et al., Preliminary Report, Intracranial Cholinergic Drug Infusion in Patients with Alzheimer's Disease, Neurosurgery, 15: 514-518, (1984).
Hollender et al., Cholinergic Approaches to the Treatment of Alzheimer's Disease, Br. Med. Bul. 42: 97-100, 1986.
Lang et al., Brain Muscarinic Receptors in Alzheimer's and Parkinson's Diseases, The Lancet, Nov. 25, 1989, p. 1279.
Metzler et al., Discriminative Stimulus Properties of Arecoline: A New Approach for Studying Central Muscarinic Receptors, Psychopharmacology, 75: 383-387, 1981.
Murray et al., Pilocarpine and Physostigmine Attenuate Spatial Memory Impairments Produced by Lesions of the Nucleus Basalis Magnocellularis, Behav. Neurosci, 100: 23-32, 1986.
Palacios et al., The Pharmacological Assessment of RS 86 (2--Ethyl--8--Methyl--2,8--Diazaspiro--4,5 Decan--1,3--Dion Hydrobromide) a Potent Specific Muscarinic Acetylcholine Receptor Agonist, Fur. J. Pharmacol., 125: 45-62, 1986.
Pradhan et al., Behavioural Effects of Arecoline in Rats, Psychopharmacology 17: 49-58, 1970.
Sitaram et al., Iluman Serial Learning: Enhancement with Arecholine and Choline and Impairment with Scopolamine, Science 201, 274-276, 1978.
Tariot et al., Multiple-Dose Arecoline Infusions in Alzheimer's Disease, Arch. Gen. Psychiatry, 45: 901-905, 1988.
Wettstein et al., Chlinical Trials with the Cholinergic Drugs RS 86 in Alzheimer's Disease (AD) and Senile Dementia of the Alzheimer Type (SDAT) Psychopharmacology, 84: 572-573, 1984.
Whitehouse et al., Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrane, Science, 215: 1237-1239, 1982.
Birdsall et al., Atlas of Science: Pharmacology, pp. 98-100 (1987).
Shutske et al., J. of Med. Chem., 31, p. 1278 (1988).
Family Health & Medical Guide, Consumer Guide Health Series, pp. 75-77 (1987).
Rodway et al., Chemical Abstracts, vol. 76, No. 14566v (1972).
Biziere Kathleen
Bourguignon Jean-Jacques
Wermuth Camille G.
Worms Paul
Bernhardt E.
Shah Mukund J.
Societe Anonyme: Sanofi
LandOfFree
Novel tricyclic derivatives which are agonists of cholinergic re does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel tricyclic derivatives which are agonists of cholinergic re, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel tricyclic derivatives which are agonists of cholinergic re will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-390392